Transcript ILUVIEN - cnsgroup11

ILUVIEN
DIABETIC MASCULAR EDEMA
• Most common cause of visual loss
• Characterised by accumulation of extracellular
fluid in the macular which occurs after the break
down of the blood-retinal barrier due to dilated
hyper-capillaries and micro-aneurysms
•Deposition of fluid causes thickening and
swelling of the macular and leads to distortion of
vision as cones are present in this area
•Primary treatment for DME is Laser
Photocoagulation and Vitrectomy.
ILUVIEN
• Recently approved as a
treatment for DME
• It weighs 0.18mg and
dispenses 0.2µg of the drug
daily
•It is the only drug therapy for
DME treatment
•In phase II trials for the
treatment of wet and dry AMD
and RVO
•Active ingredient is
fluocinolone acetonide
DELIVERY
• injected intra-vitreally using a
25 gauge needle.
• minimally invasive procedure,
no need for suture
•Non-erodible insert
•Designed to deliver drug for up
to 3 years
•Easier to deliver then retisert
because of its smaller size